Expressions of Thymidylate Synthase, Thymidine Phosphorylase, Class III β-tubulin, and Excision Repair Cross-complementing Group 1 Predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or Cisplatin

摘要: Objective: To evaluate the role of class III β-tubulin (TUBB3), thymidylate synthase (TS), thymidine phosphorylase (TP), and excision repair cross-complementing group 1 (ERCC1) in clinical outcome advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin. Methods: The data tumor specimens from 57 first-line (cohort 1, n=36) cisplatin 2, n=21) were retrospectively collected, TUBB3, TS, TP, ERCC1 expressions detected by real-time quantitative PCR. associations between biomarkers response survival analyzed statistically. Results: median age was years (range: 27–75 years) with 38 males 19 females. Of all patients, rates high low TP TS 57.1%, 27.6% (P=0.024), 55.2%, 28.6% (P=0.042), respectively. Among cohort overall survivals TUBB3 61.1% vs. 33.3% (P=0.095) 13.8 months 6.6 (P=0.019), respectively; rate (87.5%) higher than that (14.3%) (P=0.01). 45.5% 20.0% respectively (P=0.361). Conclusion: could predict capecitabine-based paclitaxel-based chemotherapy. These results will be further confirmed future large samples.